6311-97-3

Usage

Uses

Used in Pharmaceutical Industry:
N-(2-pyridin-2-ylethyl)butan-1-amine is used as a key intermediate in the synthesis of various pharmaceutical drugs. Its unique structure allows it to be incorporated into the development of medications with specific therapeutic properties.
Used in Antihistamine Medications:
N-(2-pyridin-2-ylethyl)butan-1-amine is used as a building block for the creation of antihistamines, which are medications that help alleviate symptoms caused by an allergic reaction, such as sneezing, itching, and a runny nose.
Used in Antipsychotic Medications:
N-(2-pyridin-2-ylethyl)butan-1-amine also serves as a precursor in the production of antipsychotic drugs, which are used to treat mental health conditions such as schizophrenia and bipolar disorder. Its presence in these medications can contribute to their efficacy in managing the symptoms of these disorders.
Used in Chemical Industry:
N-(2-pyridin-2-ylethyl)butan-1-amine is used as a precursor in the production of other organic compounds, highlighting its importance in the synthesis of a wide range of chemical products. Its versatility in chemical reactions makes it a valuable component in various chemical processes.

InChI:InChI=1/C11H18N2/c1-2-3-8-12-10-7-11-6-4-5-9-13-11/h4-6,9,12H,2-3,7-8,10H2,1H3

Upstream product

• 100-69-6 2-vinylpyridine 
• 109-73-9 N-butylamine 
• 109-06-8 α-picoline 
• 2706-56-1 2-(aminoethyl)pyridine 
• 71-36-3 butan-1-ol 
• 103-74-2 2-(2-Hydroxyethyl)pyridine 

Relevant academic research and scientific papers

Catalyst Evolution in Ruthenium-Catalyzed Coupling of Amines and Alcohols

We describe the mechanism, scope, and catalyst evolution for our ruthenium-based coupling of amines and alcohols, which proceeds from a [(η6-cymene)RuCl(PyCH2PtBu2)]OTf (1) precatalyst. The method selectively produces secondary amines through a hydrogen borrowing mechanism and is successfully applied to several heterocyclic carbinol substrates. Under the reaction conditions, precatalyst 1 evolves through a series of catalytic intermediates: [(η6-cymene)RuH(PyCH2PtBu2)]OTf (3), [Ru3H2Cl2(CO)(PyCH2PtBu2)2{μ-(C5H3N)CH2PtBu2}]OTf (4), and a diastereomeric pair of [Ru2HCl(CO)2(PyCH2PtBu2)2(μ-O2CnPr)]X (trans-5, X = Cl; cis-6, X = OTf). The structures of 4 and 6 were established by single-crystal X-ray diffraction. A study of catalytic activity shows that 4 is a dormant (but alive) form of the catalyst, whereas 5 and 6 are the ultimate dead forms. Electrochemical studies show that 4 is redox active and undergoes electrochemically reversible one-electron oxidation at E1/2 = 0.442 V (vs Fc+/Fc) in CH2Cl2 solution. We discuss the factors that govern the formation of 3-6 and the role of selective ruthenium carbonylation, which is essential for enabling generation of the active catalyst. We also connect these discoveries to the identification of conditions for amination of aliphatic alcohols, which eluded us until we understood the catalyst's complex speciation behavior.

SOMATOSTATINE RECEPTOR SUBTYPE 1 (SSTR1) ACTIVE COMPOUNDS AND THEIR USE IN THERAPY

This invention relates to a group of novel somatostatin receptor subtype 1 (SSTR1) active compounds and pharmaceutical compositions comprising said compounds. Furthermore, the invention concerns the use of said compounds for the treatment or prevention of